52 completed, 13 terminated, 11 recruiting, 6 unknown. 95 Phase 1, 35 Phase 2.
Follow Amyloidosis: new trials by email Literature Review of Amyloidosis trials Research Report on Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis GPRC5D CART - Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis | Phase 1 | Not yet recruiting | Hadassah Medical Organization | 160 | 2026-11-01 | 2026-10-20 |
| Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy GEB-101 Injection - Hereditary Corneal Dystrophy, Corneal Abnormality | Phase 1 / Phase 2 | Not yet recruiting | GenEditBio Limited | 30 | 2026-10-01 | 2026-09-10 |
| A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis FKC289 infusion - Primary Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Fosun Kairos Biotechnology Co., Ltd. | 32 | 2026-08-01 | 2026-08-14 |
| PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis [18F]Fluselenamyl (FSA) - Cardiac Amyloidosis | Phase 1 | Enrolling by invitation | Washington University School of Medicine | 50 | 2026-01-14 | 2026-08-18 |
| Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis GC012F Injection - Relapsed/Refractory AL Amyloidosis | Phase 1 | Recruiting | Gracell Biotechnologies (Shanghai) Co., Ltd. | 9 | 2025-10-29 | 2026-07-23 |
| Test-retest Study With [18F]FBB in Cardiac Amyloidosis Florbetaben F18 - Cardiac Amyloidosis | Phase 1 | Completed | Lantheus Germany GmbH | 15 | 2025-10-21 | 2026-10-23 |
| Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load 124I AT-01 - Cryopyrin-Associated Periodic Syndromes, Amyloidosis | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2025-09-10 | 2026-05-19 |
| A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. AZD0120 - Relapsed AL Amyloidosis, Refractory AL Amyloidosis | Phase 1 / Phase 2 | Recruiting | Alexion Pharmaceuticals, Inc. | 91 | 2025-08-18 | 2026-07-02 |
| A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma JNJ-79635322, Daratumumab, Pomalidomide - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 | Recruiting | Janssen Research & Development, LLC | 276 | 2024-12-04 | 2026-09-25 |
| Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis Elranatamab - AL Amyloidosis | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 49 | 2024-11-01 | 2026-08-19 |
| Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy Genistein - Amyloid Cardiomyopathy | Phase 1 / Phase 2 | Recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 20 | 2024-09-27 | 2025-06-15 |
| Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis NXC-201 CAR-T - Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Nexcella Inc. | 45 | 2024-06-05 | 2026-07-14 |
| Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt) Dobutrex - ATTR Amyloidosis Wild Type | Phase 1 / Phase 2 | Recruiting | Steen Hvitfeldt Poulsen | 15 | 2024-04-08 | 2026-06-01 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion ABBV-383 (Etentamig) - Immunoglobulin Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Recruiting | AbbVie | 76 | 2024-04-01 | 2026-05-13 |
| Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 weeks) - AL Amyloidosis, Amyloidosis | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 37 | 2024-02-15 | 2026-08-19 |
| Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) Venetoclax, Dexamethasone, Daratumumab - AL Amyloidosis, Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Withdrawn | Alfred Chung, MD | 2024-01-08 | 2025-03-06 | |
| A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate - Systemic Amyloidosis | Phase 1 | Recruiting | University of Tennessee Graduate School of Medicine | 31 | 2023-09-18 | 2026-07-24 |
| An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis STI-6129 - Light Chain (AL) Amyloidosis | Phase 1 | Withdrawn | Sorrento Therapeutics, Inc. | 2023-09-01 | 2023-04-28 | |
| FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis FKC288 - Light Chain Amyloidosis | Phase 1 | Unknown | Nanjing University School of Medicine | 12 | 2023-08-29 | 2023-11-15 |
| A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) SAR445514 - Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis | Phase 1 | Terminated | Sanofi | 32 | 2023-05-15 | 2026-05-27 |
Showing 20 of 95. Sign in to see all of them.
Immunoglobulin Light-chain Amyloidosis (64) · Multiple Myeloma (31) · Lymphoma, Non-Hodgkin (22) · Neoplasms, Plasma Cell (22) · Burkitt Lymphoma (21) · Leukemia, Lymphocytic, Chronic, B-Cell (21) · Lymphoma, Follicular (21) · Lymphoma, Large B-Cell, Diffuse (21) · Lymphoma, Large-Cell, Immunoblastic (21) · Lymphoma, Mantle-Cell (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (21) · Hodgkin Disease (20) · Myeloproliferative Disorders (20) · Leukemia (19)
Metabolic Diseases (95) · Nutritional and Metabolic Diseases (95) · Proteostasis Deficiencies (94) · Immune System Diseases (70) · Neoplasms (70) · Neoplasms by Histologic Type (70) · Immunoproliferative Disorders (69) · Paraproteinemias (69) · Lymphoproliferative Disorders (67) · Neoplasms, Plasma Cell (48) · Cardiovascular Diseases (34) · Vascular Diseases (32) · Blood Protein Disorders (31) · Hematologic Diseases (31)
Dexamethasone (18) · Calcium Dobesilate (11) · Cyclophosphamide (7) · Peripheral Blood Stem Cell Transplantation (6) · ixazomib (6) · daratumumab (5) · dexamethasone acetate (5) · miridesap (5) · pomalidomide (5) · Bortezomib (4) · Filgrastim (4) · auricularum (4) · dexamethasone 21-phosphate (4) · venetoclax (4) · Cyclosporine (3)
GlaxoSmithKline (7) · National Cancer Institute (NCI) (5) · University of Tennessee (4) · M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · Alexion Pharmaceuticals, Inc. (2) · Attralus, Inc. (2) · Boston Medical Center (2) · Eidos Therapeutics, a BridgeBio company (2) · Fred Hutchinson Cancer Center (2) · Janssen Research & Development, LLC (2) · Memorial Sloan Kettering Cancer Center (2) · Millennium Pharmaceuticals, Inc. (2) · Northwestern University (2) · Proclara Biosciences, Inc. (2)
United States (65) · United Kingdom (14) · Spain (8) · France (7) · Netherlands (6) · Australia (5) · Italy (5) · Canada (4) · China (4) · Greece (4) · Israel (4) · Germany (3) · Japan (3) · Sweden (3) · Belgium (2)
Vaishali Sanchorawala, MD (3) · Alan Solomon, MD (2) · Raymond Comenzo, MD (2) · Richard K. Burt, MD (2) · Adam Cohen, MD (1) · Alex A. Adjei, MD, PhD (1) · Alfred Chung, MD (1) · Andrew Eisenberger, MD (1) · Andrew Stephens, MD, PhD (1) · Angela Dispenzieri (1) · Anita D'Souza, MD (1)
PMID 40226119, PMID 41100731, PMID 19498019, PMID 20522711, PMID 20724537, PMID 21562045, PMID 22259028, PMID 22517904, PMID 24004667, PMID 24474568, PMID 25202139, PMID 26176329, PMID 26858336, PMID 27381904, PMID 27872060, PMID 28550039, PMID 29298867, PMID 31119947, PMID 31978210, PMID 32499241, PMID 34175043, PMID 34215024, PMID 34397539, PMID 34521113, PMID 34786667, PMID 35152886, PMID 35737873, PMID 35810311, PMID 37212440, PMID 37277877, PMID 39555828, PMID 41002250, PMID 41388232, PMID 41714853, PMID 41920709, PMID 42312318, PMID 42362866
2023 (3), 2015 (2), 2017 (2), 2019 (2), U01CA069912 (2), 2014 (1), P01CA015396 (1), P01CA078902 (1), P30CA006973 (1), P30CA015083 (1), P30CA015704 (1), P30CA016058 (1), P30CA016087 (1), P30CA023074 (1), P30CA072720 (1)